Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice

Molecular Therapy

Volumn 22, Issue 7, 2014, Pages 1333-1341

  Gao, Xianjun ^a   Zhao, Jingwen ^a   Han, Gang ^a   Zhang, Yajie ^a   Dong, Xue ^a   Cao, Limin ^a   Wang, Qingsong ^a   Moulton, Hong M ^b   Yin, Hai Fang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; M12 PEPTIDE PHOSPHORODIAMIDATE MORPHOLINO CONJUGATE; UNCLASSIFIED DRUG; MORPHOLINO OLIGONUCLEOTIDE; PEPTIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOPANNING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; GRIP STRENGTH; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYOBLAST; NONHUMAN; PHAGE DISPLAY; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SCREENING TEST; SKELETAL MUSCLE; ANIMAL; CHEMISTRY; DEFICIENCY; DUCHENNE MUSCULAR DYSTROPHY; METABOLISM; MUSCULAR DYSTROPHY, ANIMAL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

ANIMALS; DYSTROPHIN; MICE, INBRED MDX; MORPHOLINOS; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES;

EID: 84903776790     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.63     Document Type: Conference Paper

References (29)

1. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 378: 595-605
2. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522
3. Yin, H, Lu, Q and Wood, M (2008). Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16: 38-45
4. Yin, H, Betts, C, Saleh, AF, Ivanova, GD, Lee, H, Seow, Y et al. (2010). Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther 18: 819-827
5. Orum, H and Wengel, J (2001). Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development. Curr Opin Mol Ther 3: 239-243. (Pubitemid 32624572
6. Yin, H, Moulton, HM, Seow, Y, Boyd, C, Boutilier, J, Iverson, P et al. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918. (Pubitemid 352762853
7. Yin, H, Moulton, H, Betts, C and Wood, M (2011). CPP-directed oligonucleotide exon skipping in animal models of Duchenne muscular dystrophy. Methods Mol Biol 683: 321-338
8. Moulton, HM (2012). Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers. Methods Mol Biol 867: 407-414
9. Ivanova, GD, Arzumanov, A, Abes, R, Yin, H, Wood, MJ, Lebleu, B et al. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36: 6418-6428
10. Yin, H, Moulton, HM, Betts, C, Seow, Y, Boutilier, J, Iverson, PL et al. (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18: 4405-4414
11. Brooks, H, Lebleu, B and Vivès, E (2005). Tat peptide-mediated cellular delivery: Back to basics. Adv Drug Deliv Rev 57: 559-577. (Pubitemid 40255561
12. Yin, H, Saleh, AF, Betts, C, Camelliti, P, Seow, Y, Ashraf, S et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide- mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19: 1295-1303
13. Samoylova, TI and Smith, BF (1999). Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 22: 460-466. (Pubitemid 29173543
14. Yin, H, Boisguerin, P, Moulton, HM, Betts, C, Seow, Y, Boutilier, J et al. (2013). Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency. Mol Ther Nucleic Acids 2: E124
15. Smith, GP (1985). Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315-1317. (Pubitemid 15000355
16. Whitney, MA, Crisp, JL, Nguyen, LT, Friedman, B, Gross, LA, Steinbach, P et al. (2011). Fluorescent peptides highlight peripheral nerves during surgery in mice. Nat Biotechnol 29: 352-356
17. Wythe, SE, DiCara, D, Taher, TE, Finucane, CM, Jones, R, Bombardieri, M et al. (2013). Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide. Ann Rheum Dis 72: 129-135
18. Heemskerk, H, Aguilerab, B, Jansonb, A, Pangb, KH, Ommena, GJ, Deutekomb, J et al. (2008). Muscle binding peptides found by phage display as delivery agent for antisense oligonucleotides. J Control Release 132: E3-e5
19. Seow, Y, Yin, H and Wood, MJ (2010). Identification of a novel muscle targeting peptide in mdx mice. Peptides 31: 1873-1877
20. Mi, Z, Lu, X, Mai, JC, Ng, BG, Wang, G, Lechman, ER et al. (2003). Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther 8: 295-305. (Pubitemid 37062839
21. McGuire, MJ, Samli, KN, Johnston, SA and Brown, KC (2004). In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol 342: 171-182. (Pubitemid 39094513
22. van Putten, M, Hulsker, M, Nadarajah, VD, van Heiningen, SH, van Huizen, E, van Iterson, M et al. (2012). The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One 7: E31937
23. Blake, DJ, Weir, A, Newey, SE and Davies, KE (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82: 291-329. (Pubitemid 34654455
24. Amantana, A, Moulton, HM, Cate, ML, Reddy, MT, Whitehead, T, Hassinger, JN et al. (2007). Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 18: 1325-1331. (Pubitemid 47122656
25. Sazani, P, Blouch, R, Weller, D, Leow, S, Kole, R, Shrewsburry S. (2009). AVI 5038: Initial Efficacy and Safety Evaluation in Cynomolgus Monkeys. Treat-NMD/NIH Conference 2009, Brussels, Belgium
26. Bussek, A, Wettwer, E, Christ, T, Lohmann, H, Camelliti, P and Ravens, U (2009). Tissue slices from adult mammalian hearts as a model for pharmacological drug testing. Cell Physiol Biochem 24: 527-536
27. Pillekamp, F, Reppel, M, Dinkelacker, V, Duan, Y, Jazmati, N, Bloch, W et al. (2005). Establishment and characterization of a mouse embryonic heart slice preparation. Cell Physiol Biochem 16: 127-132. (Pubitemid 41199910
28. Wu, B, Lu, P, Cloer, C, Shaban, M, Grewal, S, Milazi, S et al. (2012). Long-Term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol 181: 392-400
29. Wu, RP, Youngblood, DS, Hassinger, JN, Lovejoy, CE, Nelson, MH, Iversen, PL et al. (2007). Cell-penetrating peptides as transporters for morpholino oligomers: Effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35: 5182-5191. (Pubitemid 47394201. of China